Orphazyme Annual Report 2019 Presentation

Return to all news

Orphazyme A/S
Investor news                                                                                                            

No. 02/2020                                                                                                                
Company Registration No. 32266355

Copenhagen, Denmark, February 20, 2020 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the Company will be hosting an investor call at which Chief Executive Officer, Kim Stratton, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Annual Report 2019. The presentation will be followed by a Q&A session.

The call will be held on Friday, February 28, 2020 at 11.00 AM CET.

Dial-in details:

  • Denmark: +45 32 72 80 42
  • France: +33 (0) 176 700 794
  • Netherlands:             +31 (0) 207 143 545
  • Sweden: +46 (0) 850 692 180
  • United Kingdom: 084 457 188 92
  • United States: +1 6315 107 495

Event Title: Orphazyme Annual Report 2019
Confirmation code: 4153337

The presentation will also be available via webcast: https://edge.media-server.com/mmc/p/f2rrgte8  

After the call, the presentation will be available via the above link.

For additional information, please contact
Orphazyme A/S

Anders Vadsholt, CFO                 +45 28 98 90 55

About Orphazyme A/S 
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com

Forward-looking statements 
This company announcement may contain certain forward-looking statements, including with respect to the timing of the Company’s clinical trials and the expected submission of application for approval of arimoclomol for the treatment of NPC in the U.S and the EU. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.


By: GlobenewsWire - 20 Feb 2020
Return to all news

Explore our database of over 50,000 companies